1	Title: Plasma proteomic signatures of adiposity are associated with cardiovascular risk factors and
2	type 2 diabetes risk in a multi-ethnic Asian population.
3	Short running title: Proteomics of adiposity
4	Authors: Charlie G.Y. Lim ¹ , Bige Ozkan ^{2,3} , Yujian Liang ¹ , Jiali Yao ¹ , Nang Ei Ei Khaing ¹ , Mary R.
5 6	Rooney ² , Chiadi E. Ndumele ^{2,3} , E Shyong Tai ^{1,4} , Josef Coresh ² , Xueling Sim ^{1*} , and Rob M. van Dam ^{1,5,*}
7	Authors affiliations:
8	¹ Saw Swee Hock School of Public Health, National University of Singapore and National University
9 10	Health System, 12 Science Drive 2, Singapore 117549 (C.G.Y.L., Y.L., J.Y., N.E.E.K., E.S.T., X.S., R.M.vD.)
11	² Department of Epidemiology and the Welch Center for Prevention, Epidemiology, and Clinical
12	Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (B.O.,
13	M.R.R., C.E.N., J.C.)
14	³ Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns
15	Hopkins University School of Medicine, Baltimore, Maryland, USA (B.O., C.E.N.)
16	⁴ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 10
17	Medical Dr, Singapore 117597 (E.S.T.)
18	⁵ Departments of Exercise and Nutrition Sciences and Epidemiology, Milken Institute School of
19	Public Health, The George Washington University, 950 New Hampshire Ave, NW, Washington, DC
20	20052 (R.M.vD.)
21	*These authors jointly supervised this work
22	
23	Corresponding Authors:
24	Xueling Sim
25	Saw Swee Hock School of Public Health, National University of Singapore
26 27	12 Science Drive 2, Singapore 117549 Tel: $\pm 65,6601,5096$
28	E-mail: <u>ephsx@nus.edu.sg</u>
29	
30 31	Rob M. van Dam Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health. The George
32	Washington University
33	950 New Hampshire Ave NW #2, Washington DC 20052
34 35	Tel: +1-202-994-9412
36	L-man. <u>Ivandam@gwu.cdu</u>

37 Abstract

38	The molecular mechanisms connecting obesity and cardiometabolic diseases are not fully
39	understood. We evaluated the associations between body mass index (BMI), waist
40	circumference (WC), and ~5,000 plasma proteins in the Singapore Multi-Ethnic Cohort
41	(MEC1). Among 410 BMI-associated and 385 WC-associated proteins, we identified protein
42	signatures of BMI and WC and validated them in an independent dataset across two
43	timepoints and externally in the Atherosclerosis Risk in Communities (ARIC) study. The
44	BMI- and WC-protein signatures were highly correlated with total and visceral body fat,
45	respectively. Furthermore, the protein signatures were significantly associated with
46	cardiometabolic risk factors and were able to differentiate between metabolically healthy and
47	unhealthy obesity. In prospective analyses, the protein signatures were strongly associated
48	with type 2 diabetes risk in MEC1 (odds ratio per SD increment in WC-protein signature =
49	2.84, 95% CI 2.47 to 3.25) and ARIC (hazard ratio = 1.97, 95% CI 1.87 to 2.07). Pathways
50	related to cell signaling, systemic inflammation, and glucose and fat metabolism were
51	overrepresented in the BMI- and WC-protein signatures. Our protein signatures have
52	potential uses for the monitoring of metabolically unhealthy obesity.

53 Article Highlights

54	•	We evaluated the associations between ~5000 plasma proteins and BMI and WC in a
55		multi-ethnic Asian population.
56	•	We identified 410 proteins associated with BMI and 385 proteins associated with WC and
57		derived protein signatures of BMI and WC, which we validated externally in a US cohort.
58	٠	Both the BMI- and WC-protein signatures were strongly associated with cardiometabolic
59		risk factors and the risk of type 2 diabetes and were enriched in pathways relating to cell
60		signaling, systemic inflammation, and glucose and fat metabolism.
61	•	Our protein signatures have potential uses for monitoring metabolically unhealthy
62		obesity.

63 Obesity is a metabolic disorder resulting from a complex interplay between genetic, 64 psychosocial, and environmental factors (1). Although obesity is a major risk factor for 65 metabolic diseases such as type 2 diabetes and cardiovascular diseases (CVDs) (2), the 66 biological mechanisms connecting obesity and these metabolic diseases are not fully 67 understood. 68 Proteins are important biomarkers for identifying biological pathways linking genetic and 69 environmental exposures to disease risk (3). Recent studies in European populations have 70 identified proteins associated with body mass index (BMI) (4-6), highlighting pathways 71 involved in lipid metabolism and inflammations that may contribute to obesity-related 72 diseases (5). However, these studies were based on platforms that covered a limited number 73 of proteins (~1100-3600 proteins), used BMI as the only measure of adiposity, and included 74 participants of predominantly European ancestry. The latter may be particularly important 75 given the well-recognized differences in the association of BMI with type 2 diabetes in 76 populations of Asian compared to European ancestry (7). Finally, previous studies did not 77 examine whether obesity-related proteins are associated with cardiometabolic health. 78 We evaluated the associations between ~5000 plasma proteins, and BMI and waist 79 circumference (WC) in a multi-ethnic Asian population comprising adults of Chinese, Malay, 80 and Indian ethnicity. Using machine learning techniques, we developed protein signatures of 81 BMI and WC and evaluated their associations with total and visceral body fat, CVD risk 82 factors, and the incidence of type 2 diabetes. 83 **Research Design and Methods**

84 Study design

An overview of this study is shown in Figure 1. Participants in this study were sampled from
the Singapore Multi-Ethnic Cohort Phase 1 (MEC1) (8). The MEC1 is a population-based

87	cohort comprising 14,465 male and female adults recruited between 2004 and 2010.
88	Oversampling of ethnic minorities (Malay and Indians) was done to achieve a good
89	representation of three major Asian ethnic groups in Singapore-Chinese, Malay, and Indian.
90	Between 2011 to 2016 (mean follow-up of 6.4 years), 6,112 participants agreed to a follow-
91	up visit. Participants completed a standardized interviewer-administered questionnaire on
92	socio-demographic characteristics, lifestyle, and medical history for both the baseline and
93	follow-up study. Height was measured without shoes on a portable stadiometer, while weight
94	was measured on a digital scale. WC was measured by trained research staff using stretch-
95	resistant tape at the mid-point between the last rib and iliac crest. Blood was drawn for
96	biomarker measurements and biobanking at -80°C.
97	At follow-up, a subset of Chinese participants underwent Dual-Energy X-ray Absorptiometry
98	(DXA) and Computed Tomography (CT) scan (9). For the DXA measurements, total body fat
99	mass, trunk fat mass, android fat mass, and lean body mass were assessed using a medium-
100	speed total body acquisition mode (Discovery Wi, Hologic, Bedford, MA, and software
101	Hologic Apex 3.01). For the CT scan, images at the inter-vertebral space L2/L3 level were
102	identified by a single observer (sliceOmatic version 5.0, Tomovision, Magog, Canada).
103	Visceral adipose tissue (VAT) at the L2/L3 level was most strongly correlated with
104	cardiovascular risk factors in Chinese adults (10). The images were analyzed by two
105	independent readers using a workstation (eFilm Workstation version 4.0, Hartland, USA),
106	and readings for VAT area and subcutaneous adipose tissue (SAT) area were averaged. The
107	average inter-observer coefficient of variation was 2.34% for SAT and 3.22% for VAT.
108	Selected MEC1 participants were profiled on the SomaScan proteomic assay. First, a random
109	sample of 720 participants with equal numbers in each sex and ethnic group were included as
110	the Population Set. The second set included 759 incident type 2 diabetes cases and 1,484
111	matched controls as the type 2 diabetes case-control (T2DCC) set. Incident type 2 diabetes

112	cases were ascertained through record linkage with a national healthcare database, self-
113	reported physician-diagnosis of diabetes at follow-up, or having a fasting blood glucose \geq
114	7mmol/L or random blood glucose \geq 11mmol/L or A1C \geq 6.5% at follow-up (11). Controls
115	were selected using risk-set sampling and were matched 1:2 according to age (\pm 5 years), sex,
116	ethnicity, and date of blood collection (± 2 years). Of 4,897 samples from 2,981 participants
117	sent to SomaLogic, 609 samples were not measured due to shipment issues. We excluded
118	samples that failed SomaLogic quality control, duplicate samples, participants from ethnic
119	groups other than Chinese, Malay, or Indian, participants with a history of heart disease at
120	baseline, and those with missing anthropometric data (Supplementary Table 1). The final
121	number of participants for analyses was 631 from the Population Set and 616 cases and 1,200
122	controls from the T2DCC Set. Written consent was obtained from all participants, and this
123	study was approved by the National University of Singapore Institutional Review Board
124	(reference code: N-18-059).
125	We externally replicated our findings in the Atherosclerosis Risk in Communities (ARIC)
125 126	We externally replicated our findings in the Atherosclerosis Risk in Communities (ARIC) Study, a population-based cohort study in the USA. Participants were male and female adults
125 126 127	We externally replicated our findings in the Atherosclerosis Risk in Communities (ARIC) Study, a population-based cohort study in the USA. Participants were male and female adults and white and African American. Details on the ARIC study have been reported elsewhere
125 126 127 128	We externally replicated our findings in the Atherosclerosis Risk in Communities (ARIC) Study, a population-based cohort study in the USA. Participants were male and female adults and white and African American. Details on the ARIC study have been reported elsewhere (12). After the exclusion of participants with diabetes (defined based on self-report diagnosis,
125 126 127 128 129	We externally replicated our findings in the Atherosclerosis Risk in Communities (ARIC) Study, a population-based cohort study in the USA. Participants were male and female adults and white and African American. Details on the ARIC study have been reported elsewhere (12). After the exclusion of participants with diabetes (defined based on self-report diagnosis, medication use, fasting glucose \geq 7mmol/L, or HbA1c \geq 6.5%) or heart diseases at baseline,
125 126 127 128 129 130	We externally replicated our findings in the Atherosclerosis Risk in Communities (ARIC) Study, a population-based cohort study in the USA. Participants were male and female adults and white and African American. Details on the ARIC study have been reported elsewhere (12). After the exclusion of participants with diabetes (defined based on self-report diagnosis, medication use, fasting glucose \geq 7mmol/L, or HbA1c \geq 6.5%) or heart diseases at baseline, we included a total of 8,428 ARIC participants with proteomic data measured on the
125 126 127 128 129 130 131	We externally replicated our findings in the Atherosclerosis Risk in Communities (ARIC) Study, a population-based cohort study in the USA. Participants were male and female adults and white and African American. Details on the ARIC study have been reported elsewhere (12). After the exclusion of participants with diabetes (defined based on self-report diagnosis, medication use, fasting glucose ≥ 7mmol/L, or HbA1c ≥ 6.5%) or heart diseases at baseline, we included a total of 8,428 ARIC participants with proteomic data measured on the SomaScan V4 platform during Visit 2 (1990-1992) in our analyses. Over a median follow-up
125 126 127 128 129 130 131 132	We externally replicated our findings in the Atherosclerosis Risk in Communities (ARIC) Study, a population-based cohort study in the USA. Participants were male and female adults and white and African American. Details on the ARIC study have been reported elsewhere (12). After the exclusion of participants with diabetes (defined based on self-report diagnosis, medication use, fasting glucose ≥ 7mmol/L, or HbA1c ≥ 6.5%) or heart diseases at baseline, we included a total of 8,428 ARIC participants with proteomic data measured on the SomaScan V4 platform during Visit 2 (1990-1992) in our analyses. Over a median follow-up duration of 19.4 years, 1,800 diabetes incident cases were ascertained based on self-reported
125 126 127 128 129 130 131 132 133	We externally replicated our findings in the Atherosclerosis Risk in Communities (ARIC) Study, a population-based cohort study in the USA. Participants were male and female adults and white and African American. Details on the ARIC study have been reported elsewhere (12). After the exclusion of participants with diabetes (defined based on self-report diagnosis, medication use, fasting glucose ≥ 7mmol/L, or HbA1c ≥ 6.5%) or heart diseases at baseline, we included a total of 8,428 ARIC participants with proteomic data measured on the SomaScan V4 platform during Visit 2 (1990-1992) in our analyses. Over a median follow-up duration of 19.4 years, 1,800 diabetes incident cases were ascertained based on self-reported diagnosis by a healthcare provider or glucose-lowering medication use reported by

135 Proteomic assay

136	Relative protein abundances were measured in plasma samples using an aptamer-based
137	technology (SomaScan V4 assay) by SomaLogic, Inc. (Boulder, Colorado, US). Details of
138	the SomaScan assay (13,14) and the reproducibility and specificity of the SomaScan assay
139	have been reported previously (15–19).
140	For this study, relative fluorescence units (RFU) for 5,284 SOMAmers were obtained. After
141	excluding 298 SOMAmers that targeted non-human proteins, 7 deprecated SOMAmers and 1
142	SOMAmer that targeted a protein whose annotation was withdrawn by the National Center
143	for Biotechnology Information (20), 4,978 SOMAmers targeting 4,775 human proteins
144	remained.
145	Statistical analysis
146	All data analyses were based on \log_2 transformed RFU and winsorized at ±5 standard
147	deviations to reduce the impact of extreme outliers. All P-values reported are from two-sided
148	tests. R version 4.2.0 was used.
149	Discovery and internal validation of protein signatures of BMI and WC
150	Using the Population Set at baseline as the discovery, we evaluated ethnic-specific
151	associations between protein levels and BMI and WC adjusted for age and sex. The ethnic-
152	specific results were pooled using fixed-effects inverse-variance meta-analysis.
153	We defined associated proteins as those that were (i) significantly associated with the trait of
154	interest (BMI or WC) at the Bonferroni corrected threshold ($P < 1.00 \times 10^{-05}$), (ii) had the
155	same direction of association across three ethnic groups, and (iii) had no evidence of
156	statistical heterogeneity using the Cochran Q test ($P_{het} > 1.00 \times 10^{-05}$). For proteins targeted by
157	multiple SOMAmers, the SOMAmer with the smallest P-value was selected. Using the
158	associated proteins, we performed 100 replicates of 10-fold cross-validation elastic net

regression analysis (21). The elastic net regression is a regularized regression method that

160	enables automatic	variable selection an	d variance reduction	(21)	The BML	protein and WC-
100	chables automatic	variable selection an	u variance reduction	(41)	. The Divit-	protein and we-

- 161 protein signatures were calculated as the weighted sum of the concentration of the selected
- 162 proteins, with the weights being the beta coefficients from the elastic net regression model.
- 163 Using the T2DCC Set as the validation, we examined cross-sectional correlations between
- the protein signatures and BMI and WC at baseline and follow-up and the correlations
- between changes in the protein signatures and changes in BMI and WC over a ~6-year
- 166 period. On a subset of Chinese participants with DXA measurements (total body fat mass,
- trunk fat mass, android fat mass, and percentage of lean mass) (n = 207) and VAT and SAT

168 measurements (n = 151), we computed the Pearson correlation coefficients.

169 Association between protein signatures and CVD risk factors

170 We evaluated associations between the protein signatures and systolic blood pressure, HDL

171 cholesterol, LDL cholesterol, triglycerides, fasting glucose, and A1C among participants in

the T2DCC Set. We used linear regression models adjusted for age, sex, and ethnicity and

standardized all predictor variables to facilitate the comparison of effect sizes. The difference

in standardized beta coefficients was evaluated using the Z-test. Participants on anti-

175 hypertensive medication were excluded from analyses involving systolic blood pressure, and

176 participants on lipid-lowering medications were excluded from analyses involving blood

177 lipids.

178 We evaluated our protein signatures' ability to differentiate between metabolically healthy

and metabolically unhealthy obesity (22) among overweight or obese individuals (BMI \geq

180 23.0 kg/m^2) in the T2DCC set at baseline. We defined metabolically unhealthy as having two

- 181 or more of the four metabolic abnormalities: (i) hypertension defined as having a systolic
- blood pressure \geq 130 mmHg or diastolic blood pressure \geq 85 mmHg; (ii) elevated fasting
- plasma glucose, defined as \geq 5.6 mmol/L, (iii) elevated triglycerides defined as \geq 1.7

184	mmol/L, and (iv) reduced HDL cholesterol defined as < 1.0 mmol/L for males and < 1.3
185	mmol/L for females. We used logistic regression models with metabolic health status as the

186 outcome and standardized protein signatures as predictors, adjusted for age, sex, ethnicity,

and BMI.

188 Association between protein signatures and type 2 diabetes incidence

- 189 We applied the BMI and WC protein signatures on the T2DCC Set to examine the
- association with type 2 diabetes incidence using logistic regression models adjusted for age,
- sex, and ethnicity. Variables were standardized to facilitate comparison with BMI and WC.

192 External validation of protein signatures in the ARIC study

- 193 Using the ARIC study, we first evaluated the associations between anthropometric
- 194 measurements and each protein in the BMI- and WC-protein signatures, adjusted for age, sex,
- race, and study center. We consider our adiposity-protein associations replicated if it was
- statistically significant at the Bonferroni threshold and directionally consistent with the ARIC
- 197 study. Next, we computed the BMI- and WC-protein signature for each ARIC participant
- using the weights identified in MEC1 and assessed their correlations with BMI and WC.
- 199 Finally, we evaluated associations between protein signatures and type 2 diabetes incidence
- using the Cox proportional hazards model, adjusted for age, sex, race, and study center.

201 Functional annotation and pathway enrichment analysis

- 202 We performed functional annotation of the proteins using the UniProt Knowledgebase (23).
- 203 We also queried the Gene Ontology (GO) (24), Kyoto Encyclopedia of Genes and Genomes
- (KEGG) (25), and Reactome (26) databases using the gprofiler2 R package version 0.2.1 (27)
- to identify functional annotations and pathways that are significantly overexpressed in the
- sets of proteins in the BMI- and WC-protein signatures using the hypergeometric test, with

207	all proteins	measured by	the SomaScan	V4 as the custom	background.	Annotations	were
-----	--------------	-------------	--------------	------------------	-------------	-------------	------

208 considered significant at a false discovery rate (FDR) corrected P-value of 0.05 (28).

209 Data and Resource Availability

- 210 Summary statistics for all measured proteins are provided in the Supplementary Tables.
- 211 Researchers can request data from the Multi-Ethnic Cohort study for scientific purposes
- through an application process at the listed website (https://blog.nus.edu.sg/sphs/data-and-
- samples-request/). Data will be shared through an institutional data-sharing agreement.

214 **Results**

- 215 The baseline characteristics of study participants are shown in **Supplementary Table 2**.
- Participants were 44.0% male and 56.0% female adults with a mean (\pm SD) age of 47.6 (\pm

12.0) years. The ethnic distribution was 34.8% Chinese, 32.6% Malay, and 32.7% Indian.

218 Discovery of the BMI and WC-protein signatures

219 Using the Population Set as discovery, we evaluated the ethnic-specific associations between

220 plasma protein levels with BMI and WC adjusted for age and sex (Supplementary Table 3).

In the meta-analysis across ethnic groups, 410 proteins were associated with BMI, and 385

222 proteins were associated with WC, with 359 proteins in common between BMI and WC

(Figure 2). Across the three ethnic groups, there was no evidence of statistical heterogeneity

 $(P_{het} > 1.00 \times 10^{-5})$, and all associations were in the same direction except one protein

225 (complement factor D) for WC, which was excluded from further analyses. All 359

226 overlapping protein-BMI and protein-WC associations were directionally consistent. The top

- four most strongly associated proteins were the same for BMI and WC, namely leptin (LEP),
- heart-type fatty acid binding protein (FABP3), insulin-like growth factor-binding protein 1
- (IGFBP1), and growth hormone receptor (GHR). We performed a look-up of the 410 BMI-
- associated proteins in three recent proteomics association studies in European adults, the

231	DIOGenes study (n = 494), the INTERVAL study (n = 2,737), and the KORA study (n = $(n = 2, 737)$).
232	4,600) (4-6). Out of the 410 BMI-associated proteins observed in our study, 90 proteins were
233	not measured in these three studies, and 263 (82%) out of the remaining 320 BMI-associated
234	proteins were directionally consistent and significant at the Bonferroni threshold in at least
235	one study (Supplementary Table 3).
236	We performed feature selection using elastic net regression analysis based on the BMI- and
237	WC-associated proteins. We identified 124 proteins for the BMI-protein signature and 125
238	proteins for the WC-protein signature, with 60 overlapping proteins in both signatures
239	(Figure 3 and Supplementary Table 4). We compared our protein signatures with the
240	published results of the Fenland Study (15). Of the 124 proteins in our BMI-protein signature,
241	28 (22.3%) were included in the Fenland Study signature for body fat percentage. Similarly,
242	of the 125 proteins in our WC-protein signature, 34 (27.2%) were included in the Fenland
243	Study signature for visceral fat mass (Supplementary Table 4).
244	Internal validation of the protein signatures
244 245	Internal validation of the protein signatures We validated the protein signatures identified in the Population Set using the T2DCC Set.
244 245 246	Internal validation of the protein signatures We validated the protein signatures identified in the Population Set using the T2DCC Set. The BMI- and WC-protein signatures were strongly correlated with BMI and WC at baseline
244 245 246 247	Internal validation of the protein signatures We validated the protein signatures identified in the Population Set using the T2DCC Set. The BMI- and WC-protein signatures were strongly correlated with BMI and WC at baseline and follow-up (r ranging from 0.778 to 0.842) (Table 1 and Supplementary Figure 1).
244 245 246 247 248	Internal validation of the protein signatures We validated the protein signatures identified in the Population Set using the T2DCC Set. The BMI- and WC-protein signatures were strongly correlated with BMI and WC at baseline and follow-up (r ranging from 0.778 to 0.842) (Table 1 and Supplementary Figure 1). Among 814 participants with both baseline and follow-up data, the changes in BMI (r =
244 245 246 247 248 249	Internal validation of the protein signatures We validated the protein signatures identified in the Population Set using the T2DCC Set. The BMI- and WC-protein signatures were strongly correlated with BMI and WC at baseline and follow-up (r ranging from 0.778 to 0.842) (Table 1 and Supplementary Figure 1). Among 814 participants with both baseline and follow-up data, the changes in BMI (r = 0.632) and WC (r = 0.438) were directly correlated with changes in the respective protein
244 245 246 247 248 249 250	Internal validation of the protein signatures We validated the protein signatures identified in the Population Set using the T2DCC Set. The BMI- and WC-protein signatures were strongly correlated with BMI and WC at baseline and follow-up (r ranging from 0.778 to 0.842) (Table 1 and Supplementary Figure 1). Among 814 participants with both baseline and follow-up data, the changes in BMI (r = 0.632) and WC (r = 0.438) were directly correlated with changes in the respective protein signatures over the same period (Supplementary Figure 2). We also examined the
244 245 246 247 248 249 250 251	Internal validation of the protein signatures We validated the protein signatures identified in the Population Set using the T2DCC Set. The BMI- and WC-protein signatures were strongly correlated with BMI and WC at baseline and follow-up (r ranging from 0.778 to 0.842) (Table 1 and Supplementary Figure 1). Among 814 participants with both baseline and follow-up data, the changes in BMI ($r =$ 0.632) and WC ($r = 0.438$) were directly correlated with changes in the respective protein signatures over the same period (Supplementary Figure 2). We also examined the correlations between changes in anthropometric measurements and changes in individual
244 245 246 247 248 249 250 251 252	Internal validation of the protein signatures We validated the protein signatures identified in the Population Set using the T2DCC Set. The BMI- and WC-protein signatures were strongly correlated with BMI and WC at baseline and follow-up (r ranging from 0.778 to 0.842) (Table 1 and Supplementary Figure 1). Among 814 participants with both baseline and follow-up data, the changes in BMI ($r =$ 0.632) and WC ($r = 0.438$) were directly correlated with changes in the respective protein signatures over the same period (Supplementary Figure 2). We also examined the correlations between changes in anthropometric measurements and changes in individual proteins in the respective signatures (Supplementary Table 5). The Pearson correlation
244 245 246 247 248 249 250 251 252 253	Internal validation of the protein signatures We validated the protein signatures identified in the Population Set using the T2DCC Set. The BMI- and WC-protein signatures were strongly correlated with BMI and WC at baseline and follow-up (r ranging from 0.778 to 0.842) (Table 1 and Supplementary Figure 1). Among 814 participants with both baseline and follow-up data, the changes in BMI (r = 0.632) and WC (r = 0.438) were directly correlated with changes in the respective protein signatures over the same period (Supplementary Figure 2). We also examined the correlations between changes in anthropometric measurements and changes in individual proteins in the respective signatures (Supplementary Table 5). The Pearson correlation coefficients ranged from 0.438 (leptin) to -0.469 (adiponectin) for changes in BMI and 0.343

- 254 (growth hormone receptor) to -0.326 (sex hormone-binding globulin) for changes in WC. All
- correlation coefficients reported here were significant (P < 0.001).
- 256 In a subset of Chinese participants with DXA and CT measurements, the BMI-protein
- signature was directly and strongly correlated with total body fat mass (r = 0.782) and
- moderately correlated with SAT (r = 0.596) and VAT (r = 0.676) (**Table 1**). In comparison
- with the BMI-protein signature, the WC-protein signature was less strongly correlated with
- total body fat mass (r = 0.619) and SAT (r = 0.433) but more strongly correlated with VAT (r
- 261 = 0.735). The scatterplots suggested a direct linear relationship between total body fat mass
- and the BMI-protein signature (beta = 4.98 kg per SD; P < 0.001) and VAT area with the
- 263 WC-protein signature (beta = $48.1 \text{ cm}^2 \text{ per SD}$; P < 0.001) (**Figure 4**).

264 Association between protein signatures and CVD risk factors

- In the T2DCC Set, all adiposity-related predictors (BMI, BMI-protein signature, WC, and
- 266 WC-protein signature) were significantly associated with higher systolic blood pressure, LDL
- 267 cholesterol, triglycerides, fasting glucose, A1C, and lower HDL cholesterol after adjustment
- for age, sex, and ethnicity (**Supplementary Table 6**). Protein signatures were significantly
- 269 more strongly associated with HDL cholesterol, triglycerides, and A1C than anthropometric
- 270 measurements. Moreover, with the exception of the BMI-protein signature and LDL
- 271 cholesterol, the associations between the BMI- and WC-protein signatures and CVD risk
- 272 factors remained statistically significant after further adjustment for BMI or WC
- 273 (Supplementary Table 6).
- 274 We also evaluated our protein signatures' ability to differentiate between metabolically
- healthy and unhealthy obesity. Among 1,262 overweight (BMI \ge 23 kg/m²) participants in
- the T2DCC set, 717 (56.8%) were metabolically unhealthy. After adjusting for age, sex,
- ethnicity, and BMI, having a higher BMI-protein signature (per SD increment, OR = 2.36,

- 278 95% CI 1.93 to 2.88) or WC-protein signature (OR = 2.75, 95% CI 2.28 to 3.32) was
- associated with a higher odds of being metabolically unhealthy. Results were similar when
- 280 we used the international BMI cut-off of 25.0 kg/m² to define overweight.

281 Association between protein signatures and type 2 diabetes incidence

- In the T2DCC Set, the BMI-protein signature (OR 2.44, 95% CI 2.15 to 2.77) and WC-
- protein signature (OR 2.84, 95% CI 2.47 to 3.25) were significantly associated with type 2
- diabetes incidence, with larger effect sizes ($P_{diff} < 0.05$) than BMI (OR 1.91, 95% CI 1.70 to
- 285 2.14) and WC (OR 2.09, 95% CI 1.86 to 2.36) (Table 2). Moreover, the associations between
- the BMI- and WC-protein signatures and type 2 diabetes remained significant after further
- adjustment for BMI and WC, respectively.
- As the effects of adiposity on insulin resistance may be modified by ethnicity (29,30), we
- conducted further analyses stratified by ethnicity (Supplementary Table 7). We found a
- stronger association between the BMI-protein signature and type 2 diabetes among Malays
- 291 (OR 2.96, 95% CI 2.33 to 3.77) and Chinese (OR 2.37, 95% CI 1.94 to 2.88) than Indians
- 292 (OR 1.91, 95% CI 1.55 to 2.35) (P-interaction = 0.019). Similarly, the WC-protein signature
- was more strongly associated with type 2 diabetes incidence among Malays (OR 3.59, 95%)
- 294 CI 2.77 to 4.67) and Chinese (OR 2.72, 95% CI 2.20 to 3.37) than Indians (OR 2.21, 95% CI
- 295 1.76 to 2.77) (P-interaction = 0.028).

296 External validation in the ARIC study

- 297 Participants in the ARIC study had a mean age of 56.7 (± 5.7) years, were mostly female
- 298 (57%), and were white (81%) or African African (19%) (Supplementary Table 8). After
- Bonferroni adjustment (P < 0.05/124 for BMI and 0.05/125 for WC), 118 (95.2%) of 124
- proteins in the BMI-protein signature and 124 (99.2%) of 125 proteins in the WC-protein
- 301 signature were directionally consistent and significantly associated with BMI and WC,

302	respectively (Supplementary	Table 4 and Supplementary	Figure 3).	Concordant with
-----	-----------------------------	---------------------------	--------------------	-----------------

- findings in MEC1, the BMI-protein signature was highly correlated with BMI (r = 0.822),
- and the WC-protein signature was highly correlated with WC (r = 0.773). A higher BMI-
- protein signature (HR per SD increment = 1.80, 95% CI 1.72 to 1.89) and WC-protein
- signature (HR = 1.97, 95% CI 1.87 to 2.07) at baseline were strongly associated with type 2
- 307 diabetes incidence over a median follow-up of 19.4 years.

308 Pathway enrichment analysis

- 309 In our pathway enrichment analysis, we identified 36 significant annotations from the BMI-
- 310 protein signature and 28 significant annotations from the WC-protein signature
- 311 (Supplementary Table 9). Pathways related to post-translational protein phosphorylation,
- the regulation of insulin-like growth factor (IGF) transport and uptake by insulin-like growth
- factor binding proteins (IGFBPs), and complement and coagulation cascades were
- significantly enriched ($P_{FDR} < 0.05$) in both BMI- and WC-protein signatures. In additional,
- 315 pathways involved in adenosine monophosphate-activated protein kinase (AMPK) signaling,
- 316 extracellular matrix (ECM) receptor interaction, and cell adhesion molecules (CAMs)- were
- significantly enriched ($P_{FDR} < 0.05$) in the WC-protein signature.

318 Discussion

- 319 We identified 410 proteins associated with BMI and 385 proteins associated with waist
- 320 circumference that were consistent across all three Asian ethnic groups (Chinese, Malay, and
- Indian) in our study population. We derived protein signatures of BMI and WC which we
- 322 validated in an independent dataset across two timepoints and externally in a cohort of US
- 323 white and African American participants. Compared to anthropometric measurements, our
- 324 protein signatures were more strongly associated with cardiometabolic risk factors and were
- 325 able to distinguish between metabolically healthy and unhealthy obesity. In prospective

326	analyses, both protein signatures were strongly associated with the risk of type 2 diabetes in
327	MEC1 and the ARIC study. Biological pathways related to post-translational protein
328	phosphorylation, regulation of IGFs and IGFBPs, coagulation cascades, AMPK signaling,
329	ECM receptor interaction, and cell adhesion were overrepresented in the BMI- and WC-
330	protein signatures.
331	Of the 410 proteins associated with BMI in our Asian cohort, over 80% of the proteins
332	measured in common were replicated in previous studies in European populations (4-6),
333	highlighting the robustness of these findings to ethnic and geographical variation. In addition,
334	we identified novel proteins that were not previously reported, most likely because of the
335	larger number of proteins represented in the proteomic assay used in our study. These include
336	serine protease high temperature requirement A1 (HTRA1), syndecan-3 (SDC3), and
337	complexin-2 (CPLX2). HTRA1 has been shown to regulate the availability of IGFs (31,32).
338	In addition, HTRA1 may inhibit adipogenesis by regulating the formation of adipocytes and
339	could be an indicator of adipose tissue dysfunction (33). Variants of the SDC3 gene have
340	been associated with obesity in Korean (34) and Taiwanese adults (35). SDC3 is involved in
341	regulating appetite through the melanocortin system (36) and may, therefore, be a potential
342	therapeutic target for treating obesity. CPLX2 may affect the translocation of glucose
343	transporter 4 (GLUT4), which plays a critical role in glucose uptake regulation (37).
344	However, it should be noted that GLUT4 translocation is an intracellular process, and
345	whether plasma levels of CPLX2 are related to this process is unclear. In addition, CPLX2
346	may also have a role in the regulation of the immune system (38). These novel adiposity-
347	related proteins, if replicated, can inform research on the pathophysiology of obesity and
348	related cardiometabolic conditions.
349	Using supervised machine learning techniques, we identified protein signatures of BMI and

350 WC and validated these across two timepoints in an independent dataset and externally in the

351	ARIC study. A large proportion (85%) of the proteins significantly associated with WC and
352	BMI in MEC1 overlapped. However, greater differences existed in proteins selected by
353	machine learning for the BMI and WC signatures, with slightly less than half of the proteins
354	overlapping. We further showed that the BMI-protein signature was highly correlated with
355	total body fat mass, whereas the WC-protein signature was more strongly correlated with
356	VAT. These findings suggest that the two protein signatures were able to capture the
357	differences in plasma proteins associated with adiposity in different anatomical
358	compartments.
359	Compared to anthropometric measures, the BMI- and WC-protein signatures were more
360	strongly associated with HDL-cholesterol, triglycerides, hemoglobin A1c levels, and the
361	incidence of type 2 diabetes. In addition, the associations of these protein signatures with
362	CVD risk factors and type 2 diabetes remained significant after further adjustment for BMI or
363	WC. These findings suggest that the protein signatures are likely to capture physiologically
364	relevant effects of body fat better than traditional measures of adiposity.
365	The identified plasma protein signatures differentiated between metabolically healthy and
366	metabolically unhealthy obesity and were associated with type 2 diabetes risk. Thus, the
367	biological pathways represented by the adiposity-related proteins may provide mechanistic
368	insights in the physiological changes associated with metabolically unhealthy obesity (39).
368 369	insights in the physiological changes associated with metabolically unhealthy obesity (39). Pathways related to complement and coagulation cascades, IGFs and IGFBPs regulation, and
368 369 370	insights in the physiological changes associated with metabolically unhealthy obesity (39). Pathways related to complement and coagulation cascades, IGFs and IGFBPs regulation, and post-translational protein phosphorylation were significantly enriched in both the BMI-and
368 369 370 371	 insights in the physiological changes associated with metabolically unhealthy obesity (39). Pathways related to complement and coagulation cascades, IGFs and IGFBPs regulation, and post-translational protein phosphorylation were significantly enriched in both the BMI-and WC-protein signatures. In addition, pathways involving AMPK signaling, ECM-receptor
368 369 370 371 372	 insights in the physiological changes associated with metabolically unhealthy obesity (39). Pathways related to complement and coagulation cascades, IGFs and IGFBPs regulation, and post-translational protein phosphorylation were significantly enriched in both the BMI-and WC-protein signatures. In addition, pathways involving AMPK signaling, ECM-receptor interaction, and CAMs were enriched in the WC-protein signature. The dysregulation of the
368 369 370 371 372 373	 insights in the physiological changes associated with metabolically unhealthy obesity (39). Pathways related to complement and coagulation cascades, IGFs and IGFBPs regulation, and post-translational protein phosphorylation were significantly enriched in both the BMI-and WC-protein signatures. In addition, pathways involving AMPK signaling, ECM-receptor interaction, and CAMs were enriched in the WC-protein signature. The dysregulation of the complement system resulting from overexpression of cytokines and adipose tissue-derived
368 369 370 371 372 373 374	insights in the physiological changes associated with metabolically unhealthy obesity (39). Pathways related to complement and coagulation cascades, IGFs and IGFBPs regulation, and post-translational protein phosphorylation were significantly enriched in both the BMI-and WC-protein signatures. In addition, pathways involving AMPK signaling, ECM-receptor interaction, and CAMs were enriched in the WC-protein signature. The dysregulation of the complement system resulting from overexpression of cytokines and adipose tissue-derived factors may lead to chronic inflammation and the development of metabolic disorders such as

376	IGFBPs have been linked to the dysregulation of fat metabolism and insulin resistance (41–
377	43). AMPK is a key enzyme involved in regulating energy and nutrient metabolism, and the
378	dysregulation of AMPK has been implicated in the development of obesity, insulin
379	resistance, and type 2 diabetes (44). The over-activation of ECM receptor signaling pathways
380	may lead to inflammation and insulin resistance (45). Elevation of CAMs has been previously
381	associated with obesity and type 2 diabetes (46,47) and may affect inflammation and
382	atherogenesis (48). Taken together, the pathways enriched in the adiposity-related protein
383	signatures depict a state of dysregulated cell signaling, systemic inflammation, and impaired
384	glucose and fat metabolism. In addition, several of the pathways (e.g., complement pathways,
385	ECM-receptor interaction, and IGFBP regulation) enriched in our adiposity-related protein
386	signatures were also enriched in type 2 diabetes-associated proteins in European populations
387	(49), underscoring the central role of obesity-related pathways in the pathogenesis of type 2
388	diabetes.
389	Previous studies have reported ethnic differences in the association between obesity and
390	insulin resistance (29,50). Khoo et al. (29) demonstrated that the association of body fat
391	percentage with insulin resistance was weaker in ethnic Indians than in Chinese and Malays
392	residing in Singapore. Furthermore, Retnakaran et al. (50) found that pre-pregnancy BMI was
393	more strongly associated with insulin resistance in East Asian women than in South Asian
394	women in Canada. Here, while associations between plasma proteins and adiposity measures
395	were consistent across ethnic groups, we observed stronger associations between the BMI-
396	and WC-protein signatures and type 2 diabetes risk in Chinese and Malays than Indians.
397	These findings suggest that ethnic differences in the associations between obesity and type 2

diabetes may be explained by differential effects of obesity-related proteins on type 2

399 diabetes.

400	We acknowledge the limitations of our study. First, the plasma proteome including both
401	secreted and leakage proteins has been shown to be informative about the current and future
402	state of health (15,19), but the concentration of leakage proteins in the plasma may not be a
403	direct reflection of its biological activity in the cells. Second, we were not able to infer
404	causality as the associations between plasma proteins and anthropometric measurements were
405	cross-sectional. Even though our participants did not have type 2 diabetes at baseline, early
406	manifestations of diabetes may have influenced plasma protein levels. Third, while studies
407	have demonstrated the specificity of the SomaScan assay (18,19), it remains possible that
408	some proteins may not be correctly identified by the SomaScan platform used in our study.
409	In conclusion, our findings on adiposity-related proteins were robust across ethnic and
410	geographically diverse groups and have potential uses for assessing and monitoring
411	metabolically adverse adiposity. While further studies are needed to evaluate the causal
412	relationship between the identified proteins and adiposity, the results from this study can lead
413	to a better understanding of the biological mechanisms relating obesity and type 2 diabetes
414	and why sub-groups of the population differ in their susceptibility to adverse effects of
415	obesity on metabolic health.

417 Acknowledgments

- 418 We thank all participants, the study team, and the investigators for their research
- 419 contributions. The MEC1 study is supported by individual research and clinical scientist
- 420 award schemes from the Singapore National Medical Research Council (NMRC, including
- 421 MOH-000271-00) and the Singapore Biomedical Research Council (BMRC), the Singapore
- 422 Ministry of Health (MOH), the National University of Singapore (NUS) and the Singapore
- 423 National University Health System (NUHS). The Atherosclerosis Risk in Communities study
- 424 has been funded in whole or in part with Federal funds from the National Heart, Lung, and
- 425 Blood Institute, National Institutes of Health, Department of Health and Human Services,
- 426 under Contract nos. (75N92022D00001, 75N92022D00002, 75N92022D00003,
- 427 75N92022D00004, 75N92022D00005). The funders had no role in the design,
- 428 implementation, analysis, and interpretation of the data.

429 Author contributions

- 430 X.S., and R.M.vD designed the study. C.G.Y.L., X.S., R.M.vD, B.O., M.R.R., C.E.N., J.C.,
- 431 J.Y., Y.L., E.S.T., N.E.E.K. contributed to the acquisition, analysis, or interpretation of data.
- 432 C.G.Y.L., X.S., R.M.vD. contributed to the drafting of manuscript. E.S.T., B.O., M.R.R.,
- 433 C.E.N., J.C. contributed to the critical revision of manuscript. X.S. is the guarantor of this
- 434 work and, as such, had full access to all the data in the study and takes responsibility for the
- integrity of the data and the accuracy of the data analysis.
- 436 **Disclaimers:** The National University of Singapore has signed a collaboration agreement
- 437 with SomaLogic to conduct SomaScan of MEC stored samples at no charge in exchange for
- the rights to analyze linked MEC phenotype data.
- 439 **Conflict of interest:** All authors report no conflict of interest.

440

441 **References**

- 442 1. Hruby A, Hu FB. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics.
 443 2015 Dec 4;33(7):673–89.
- Riaz H, Khan MS, Siddiqi TJ, Usman MS, Shah N, Goyal A, et al. Association
 Between Obesity and Cardiovascular Outcomes: A Systematic Review and Metaanalysis of Mendelian Randomization Studies. JAMA Netw Open. 2018 Nov
 2;1(7):e183788–e183788.
- 448 3. Hanash S. Disease proteomics. Nature. 2003 Mar 13;422(6928):226–32.
- 449 4. Carayol J, Chabert C, Di Cara A, Armenise C, Lefebvre G, Langin D, et al. Protein
 450 quantitative trait locus study in obesity during weight-loss identifies a leptin regulator.
 451 Nat Commun. 2017 Dec 1;8(1).
- 452 5. Zaghlool SB, Sharma S, Molnar M, Matías-García PR, Elhadad MA, Waldenberger M,
 453 et al. Revealing the role of the human blood plasma proteome in obesity using genetic
 454 drivers. Nat Commun. 2021 Feb 24;12(1):1–13.
- Goudswaard LJ, Bell JA, Hughes DA, Corbin LJ, Walter K, Davey Smith G, et al.
 Effects of adiposity on the human plasma proteome: observational and Mendelian
 randomisation estimates. Int J Obes (Lond). 2021 Oct;45(10):2221–9.
- Ma RCW, Chan JCN. Type 2 diabetes in East Asians: similarities and differences with
 populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281(1):64–91.
- 460 8. Tan KHX, Tan LWL, Sim X, Tai ES, Lee JJM, Chia KS, et al. Cohort Profile: The
 461 Singapore Multi-Ethnic Cohort (MEC) study. Int J Epidemiol. 2018;47(3):699-699j.
- 462 9. Khaing NEE, Shyong TE, Lee J, Soekojo CY, Ng A, Van Dam RM. Epicardial and
 463 visceral adipose tissue in relation to subclinical atherosclerosis in a Chinese
 464 population. PLoS One. 2018 Apr 1;13(4):e0196328.
- 10. Ng AC, Wai DC, Tai ES, Ng KM, Chan LL. Visceral adipose tissue, but not waist circumference is a better measure of metabolic risk in Singaporean Chinese and Indian men. Nutr Diabetes. 2012 Aug 6;2(8):e38–e38.
- 468 11. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards
 469 of Medical Care in Diabetes—2021. Diabetes Care. 2021 Jan
 470 1;44(Supplement_1):S15–33.
- 471 12. Steffen BT, Tang W, Lutsey PL, Demmer RT, Selvin E, Matsushita K, et al. Proteomic
 472 analysis of diabetes genetic risk scores identifies complement C2 and neuropilin-2 as
 473 predictors of type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) Study.
 474 Diabetologia. 2022 Jan 1;66(1):105–15.
- Rohloff JC, Gelinas AD, Jarvis TC, Ochsner UA, Schneider DJ, Gold L, et al. Nucleic
 Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as
 Diagnostic and Therapeutic Agents. Mol Ther Nucleic Acids. 2014;3(10):e201.
- 478 14. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, et al. Aptamer-Based
 479 Multiplexed Proteomic Technology for Biomarker Discovery. PLoS One.
 480 2010;5(12):e15004.
- 481 15. Williams SA, Kivimaki M, Langenberg C, Hingorani AD, Casas JP, Bouchard C, et al.

- Plasma protein patterns as comprehensive indicators of health. Nat Med. 2019 Dec 2;25(12):1851–7.
- Kim CH, Tworoger SS, Stampfer MJ, Dillon ST, Gu X, Sawyer SJ, et al. Stability and
 reproducibility of proteomic profiles measured with an aptamer-based platform. Sci
 Reports 2018 81. 2018 May 30;8(1):1–10.
- Tin A, Yu B, Ma J, Masushita K, Daya N, Hoogeveen RC, et al. Reproducibility and
 Variability of Protein Analytes Measured Using a Multiplexed Modified Aptamer
 Assay. J Appl Lab Med. 2019 Jul 1;4(1):30.
- 490 18. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic
 491 atlas of the human plasma proteome. Nature. 2018 Jun 6;558(7708):73–9.
- 492 19. Emilsson V, Ilkov M, Lamb JR, Finkel N, Gudmundsson EF, Pitts R, et al. Co493 regulatory networks of human serum proteins link genetics to disease. Science. 2018
 494 Aug 8;361(6404):769.
- 495 20. NCBI. LOC652493 ig kappa chain V-I region HK102-like [Homo sapiens (human)] 496 Gene NCBI [Internet]. 2011.
- Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc
 Ser B (Statistical Methodol. 2005 Apr 1;67(2):301–20.
- 499 22. Blüher M. Metabolically Healthy Obesity. Endocr Rev. 2020 Jun 1;41(3):405–20.
- Bateman A, Martin MJ, Orchard S, Magrane M, Ahmad S, Alpi E, et al. UniProt: the
 Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 2023 Jan
 6;51(D1):D523–31.
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene
 Ontology: tool for the unification of biology. Nat Genet. 2000 May;25(1):25.
- 505 25. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic
 506 Acids Res. 2000 Jan 1;28(1):27–30.
- 507 26. Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The
 508 Reactome Pathway Knowledgebase. Nucleic Acids Res. 2018 Jan 1;46(Database
 509 issue):D649.
- 510 27. Kolberg L, Raudvere U, Kuzmin I, Vilo J, Peterson H. gprofiler2 -- an R package for
 511 gene list functional enrichment analysis and namespace conversion toolset g:Profiler.
 512 F1000Research. 2020 Jul 15;9:709.
- 513 28. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and
 514 Powerful Approach to Multiple Testing. J R Stat Soc Ser B. 1995 Jan 1;57(1):289–
 515 300.
- 516 29. Khoo CM, Khee-Shing Leow M, Sadananthan SA, Lim R, Venkataraman K, Khoo
 517 EYH, et al. Body Fat Partitioning Does Not Explain the Interethnic Variation in
 518 Insulin Sensitivity Among Asian Ethnicity: The Singapore Adults Metabolism Study.
 519 Diabetes. 2014 Mar 1;63(3):1093–102.
- Son Stephen S

- Hou J, Clemmons DR, Smeekens S. Expression and characterization of a serine
 protease that preferentially cleaves insulin-like growth factor binding protein-5. J Cell
 Biochem. 2005 Feb 15;94(3):470–84.
- Jacobo SMP, DeAngelis MM, Kim IK, Kazlauskas A. Age-Related Macular
 Degeneration-Associated Silent Polymorphisms in HtrA1 Impair Its Ability To
 Antagonize Insulin-Like Growth Factor 1. Mol Cell Biol. 2013 May 1;33(10):1976.
- Tiaden AN, Bahrenberg G, Mirsaidi A, Glanz S, Blüher M, Richards PJ. Novel
 Function of Serine Protease HTRA1 in Inhibiting Adipogenic Differentiation of
 Human Mesenchymal Stem Cells via MAP Kinase-Mediated MMP Upregulation.
 Stem Cells. 2016 Jun 1;34(6):1601–14.
- Ha E, Kim MJ, Choi BK, Rho JJ, Oh DJ, Rho TH, et al. Positive Association of
 Obesity with Single Nucleotide Polymorphisms of Syndecan 3 in the Korean
 Population. J Clin Endocrinol Metab. 2006 Dec 1;91(12):5095–9.
- 536 35. Chang BCC, Hwang LC, Huang WH. Positive Association of Metabolic Syndrome
 537 with a Single Nucleotide Polymorphism of Syndecan-3 (rs2282440) in the Taiwanese
 538 Population. Int J Endocrinol. 2018;2018.
- 36. Reizes O, Benoit SC, Strader AD, Clegg DJ, Akunuru S, Seeley RJ. Syndecan-3
 Modulates Food Intake by Interacting with the Melanocortin/AgRP Pathway. Ann N Y
 Acad Sci. 2003 Jun 1;994(1):66–73.
- 542 37. Pavarotti MA, Tokarz V, Frendo-Cumbo S, Bilan PJ, Liu Z, Zanni-Ruiz E, et al.
 543 Complexin-2 redistributes to the membrane of muscle cells in response to insulin and
 544 contributes to GLUT4 translocation. Biochem J. 2021 Jan 29;478(2):407–22.
- Tsuru E, Oryu K, Sawada K, Nishihara M, Tsuda M. Complexin 2 regulates secretion
 of immunoglobulin in antibody-secreting cells. Immunity, Inflamm Dis. 2019 Dec
 1;7(4):318–25.
- Iacobini C, Pugliese G, Blasetti Fantauzzi C, Federici M, Menini S. Metabolically
 healthy versus metabolically unhealthy obesity. Metabolism. 2019 Mar 1;92:51–60.
- Shim K, Begum R, Yang C, Wang H. Complement activation in obesity, insulin
 resistance, and type 2 diabetes mellitus. World J Diabetes. 2020 Jan 1;11(1):1.
- Friedrich N, Thuesen B, Jrøgensen T, Juul A, Spielhagen C, Wallaschofksi H, et al.
 The Association Between IGF-I and Insulin Resistance: A general population study in
 Danish adults. Diabetes Care. 2012 Apr;35(4):768.
- Haywood NJ, Slater TA, Matthews CJ, Wheatcroft SB. The insulin like growth factor
 and binding protein family: Novel therapeutic targets in obesity & diabetes. Mol
 Metab. 2019 Jan 1;19:86.
- 43. Clemmons DR. Role of IGF-binding proteins in regulating IGF responses to changes
 in metabolism. J Mol Endocrinol. 2018 Jul 1;61(1):T139–69.
- 560 44. Steinberg GR, Hardie DG. New insights into activation and function of the AMPK.
 561 Nat Rev Mol Cell Biol. 2023 Apr;24(4):255–72.
- Lin D, Chun TH, Kang L. Adipose extracellular matrix remodelling in obesity and insulin resistance. Biochem Pharmacol. 2016 Nov 1;119:8–16.

- 46. Hegazy GA, Awan Z, Hashem E, Al-Ama N, Abunaji AB. Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications. J Int Med Res. 2020;48(4):1–11.
- Miller MA, Cappuccio FP. Cellular adhesion molecules and their relationship with
 measures of obesity and metabolic syndrome in a multiethnic population. Int J Obes
 2006 308. 2006 Mar 7;30(8):1176–82.
- 48. Hope SA, Meredith IT. Cellular adhesion molecules and cardiovascular disease. Part I.
 Their expression and role in atherogenesis. Intern Med J. 2003 Aug 1;33(8):380–6.
- 49. Gudmundsdottir V, Zaghlool SB, Emilsson V, Aspelund T, Ilkov M, Gudmundsson
 573 EF, et al. Circulating Protein Signatures and Causal Candidates for Type 2 Diabetes.
 574 Diabetes. 2020 Aug 1;69(8):1843.
- 575 50. Retnakaran R, Hanley AJG, Connelly PW, Sermer M, Zinman B. Ethnicity Modifies
 576 the Effect of Obesity on Insulin Resistance in Pregnancy: A Comparison of Asian,
 577 South Asian, and Caucasian Women. J Clin Endocrinol Metab. 2006 Jan 1;91(1):93–7.
- 578

580 Tables

- 581 Table 1. Pearson correlation coefficients between body mass index (BMI) and waist circumference
- 582 (WC) protein signatures and anthropometric, DXA, and CT adiposity measurements in the T2DCC
- 583 Set.

	BMI signature		WC signature			
	Cases	Controls	Combined	Cases	Controls	Combined
Anthropometric measured	ments at base	line *				
BMI, kg/m ²	0.815	0.847	0.842	0.675	0.731	0.726
WC, cm	0.639	0.717	0.716	0.675	0.798	0.778
Anthropometric measurements at follow-up †						
BMI, kg/m ²	0.809	0.829	0.823	0.696	0.712	0.713
WC, cm	0.712	0.742	0.752	0.726	0.791	0.783
DXA measurements ‡	L					
Total body fat mass, kg	0.756	0.789	0.782	0.628	0.583	0.619
Lean mass, %	-0.482	-0.484	-0.488	-0.270	-0.171	-0.232
Android fat mass, kg	0.755	0.787	0.787	0.706	0.689	0.717
Trunk fat mass, kg	0.764	0.812	0.801	0.685	0.665	0.691
CT measurements §	I					
SAT volume, cm ²	0.499	0.641	0.596	0.418	0.378	0.433
VAT volume, cm ²	0.542	0.719	0.676	0.603	0.776	0.735

All correlation coefficients were statistically significant at P <0.001. Abbreviations: BMI, body mass

585 index; Computed Tomography, CT; DXA, Dual-Energy X-ray Absorptiometry; SAT, subcutaneous

adipose tissue; T2DCC, type 2 diabetes case control; VAT, visceral adipose tissue; WC, waist

587 circumference.

* Measured among all participants in the T2DCC Set at baseline; n = 616 for cases, 1,200 for controls,

and 1,816 when combined.

[†] Measured among all participants in the T2DCC Set at follow-up; n = 327 for cases, 487 for controls,

and 814 when combined.

592 \ddagger Measured in a subset of Chinese participants at follow-up; n = 69 for cases, 138 for controls, and

593 207 when combined.

§ Measured in a subset of Chinese participants at follow-up; n = 51 for cases, 100 for controls, and

595 151 when combined.

- 597 **Table 2.** Associations between anthropometric measurements, protein signatures of adiposity, and the
- 598 incidence of type 2 diabetes.

	OR (95% CI)	P-value	P _{diff} *
BMI	1.91 (1.70, 2.14)	1.95E-28	
BMI-protein signature	2.44 (2.15, 2.77)	1.19E-42	0.005
BMI-protein signature adjusted for	2.69 (2.18, 3.32)	3.80E-20	
BMI			
WC	2.09 (1.86, 2.36)	2.09E-33	
WC-protein signature	2.84 (2.47, 3.25)	1.64E-50	0.001
WC-protein signature adjusted for	2.69 (2.23, 3.25)	6.25E-25	
WC			

599 All predictor variables were expressed as per 1 SD increment to facilitate the comparison of effect

sizes. All models were adjusted for age, sex, and ethnicity.

601 Abbreviations: BMI, body mass index; WC, waist circumference.

602 * P-value for difference between the standardized coefficients for BMI and the BMI-protein signature,

and the coefficients between WC and the WC-protein signature, calculated using the Z test.

605 Figures



606

607 Figure 1. Overview of the study design.* Measured in a subset of Chinese participants in the MEC1

608 (n = 207) at follow-up. † Measured in a subset of Chinese participants in the MEC1 (n = 151) at

609 follow-up. ‡ Cross-sectional correlations between protein signatures and anthropometric

610 measurements at baseline (n = 1,816) and follow-up (n = 814). Longitudinal correlations between the

611 change in protein signatures and change in anthropometric measurements in participants with data

612 across two timepoints (n = 814). Abbreviations: ARIC, Atherosclerosis Risk in Communities; BMI,

body mass index; CT, computed tomography; CVD, cardiovascular disease; DXA, dual-energy X-ray

```
absorptiometry; MEC1, Multi-Ethnic Cohort Phase 1; T2DCC, T2D case-control; WC, waist
```

615 circumference.

- 616
- 617
- 618
- 619
- 620



Figure 2. (a) Volcano-plot of $-\log_{10}(P_{BMI})$ against $\log_2(\text{fold change})$ per kg/m² increment of BMI. (b) Volcano-plot of $-\log_{10}(P_{WC})$ against $\log_2(\text{fold change})$ per cm increment of WC. Dashed lines represent the threshold for statistical significance after Bonferroni correction. (c) Scatterplot of the beta coefficients for WC against the beta coefficients for BMI. Text annotations are Entrez Gene symbols and the full protein names are provided in Supplementary Table 4. (d) Venn diagram of the number of proteins that were significantly associated with BMI and WC at the Bonferroni threshold. Abbreviations: BMI, body mass index; WC, waist circumference.

629

630



632	33
633	Figure 3. Proteins in the BMI-protein signature (outer circle) and WC-protein signature (inner circle).
634	The colours represent the direction (red = increase, blue = decrease, $grey = not$ in signature) while the
635	intensity of the colours represents the magnitudes of the standardized beta coefficients from elastic net
636	regression. Beta coefficients were standardized to facilitate the comparison of effect sizes across the
637	BMI and WC. The bottom right segment represents the shared proteins between the BMI-protein and
638	WC-protein signature. Moving anticlockwise, the top right segment represents proteins that are only
639	in the WC-protein signature. Finally, the last segment on the top left represents proteins that are only
640	in the BMI-protein signature. Text annotations are Entrez Gene symbols and the full protein names
641	are provided in Supplementary Table 5. Abbreviations: BMI, body mass index; WC, waist
642	circumference.

643





647 Figure 4. Scatterplots of (a) total body fat mass against BMI-protein signature in 207 Chinese

648 participants with DXA and (b) visceral adipose tissue volume against the WC-protein signature in 151

649 Chinese participants with CT. Linear regression was fitted with the shaded region representing the

650 95% confidence intervals and the dotted lines representing the 95% prediction intervals.

651 Abbreviations: CT, computed tomography; DXA, dual-energy X-ray absorptiometry; SD, standard

652 deviation.

653



654 Supplementary Figures

Supplementary Figure 1. Scatterplots of (a) BMI against BMI-protein signature at baseline (b) WC
against WC-protein signature at baseline, (c) BMI against BMI-protein signature at follow-up, and (d)
WC against WC-protein signature at follow-up in the T2DCC Set. The diagonal lines represent the y
= x line. Abbreviations: BMI, body mass index; T2DCC, type 2 diabetes case control; WC, waist
circumference.

661

655



663Change in BMI-protein signature, SDChange in WC-protein signature, SD664Supplementary Figure 2. Scatterplots of (a) change in BMI against change in BMI-protein signature,

and (b) change in WC against change in WC-protein signature over a ~6-year period in the T2DCC

set. The diagonal lines represent the y = x line. Abbreviations: BMI, body mass index; SD, standard

deviation; T2DCC, type 2 diabetes case control; WC, waist circumference.



670 Supplementary Figure 3. Comparison of the beta coefficients for the associations between plasma

671 proteins and BMI/WC between the Singapore Multi-ethnic cohort Phase 1 (MEC1) and the

672 Atherosclerosis Risk in Communities (ARIC) study for (a) the BMI-protein signature and (b) the WC-

673 protein signature. Plasma protein levels in relative fluorescence units (RFU) were quantified using the

674 SomaScan V4 assay in both studies. Each point corresponds to each protein in the respective protein

signatures (n = 124 for the BMI-protein signature and n = 125 for the WC-protein signature).

676 Abbreviations: BMI, body mass index; WC, waist circumference.